Share

September 2020; 7 (5) Clinical/Scientific NotesOpen Access

COVID-19 in MS

Initial observations from the Pacific Northwest

James D. Bowen, Justine Brink, Ted R. Brown, Elisabeth B. Lucassen, Kyle Smoot, Annette Wundes, Pavle Repovic
First published May 26, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000783
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1566

Share

Article Information

vol. 7 no. 5 e783
DOI: 
https://doi.org/10.1212/NXI.0000000000000783
PubMed: 
32457226
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 14, 2020
  • Accepted in final form May 7, 2020
  • First Published May 26, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. James D. Bowen, MD,
    2. Justine Brink, DO, MPH,
    3. Ted R. Brown, MD, MPH,
    4. Elisabeth B. Lucassen, MD,
    5. Kyle Smoot, MD,
    6. Annette Wundes, MD and
    7. Pavle Repovic, MD, PhD
  1. James D. Bowen, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Biogen IDEC, Celgene, EMD Serono, Genentech, Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen IDEC, Celgene, EMD Serono, Genentech, Novartis

    Speakers' Bureaus:

    1. Biogen IDEC, Celgene, EMD Serono, Genentech, Novartis

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Abbvie, Alkermes, Biogen IDEC, Bristol Meyers Squibb, Celgene, Genentech, Genzyme, Novartis, Roche

    Research Support, Government Entities:

    1. NIA Grant #U01AG006781 Co-investigator, 5 years PCORI Grant# MS-1610-37115 Co-Investigator, 5 years. NIAID, Immune Tolerance Network UM1 AI 109565, Protocol ITN077AI Site Principal Investigator, 5 years Stock/Stock Options, Medical Equipment & Materials: Amgen

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Justine Brink, DO, MPH,
    3. Scientific Advisory Boards:

    1. (1) Biogen Idec Inc.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Teva Pharmaceuticals Ltd.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) National MS Society Physicians Council

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Ted R. Brown, MD, MPH,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, honoraria, speaker's bureau, travel to give presentation (2) EMD Serono, honoraria, travel to give presentation (3) Multiple Sclerosis Foundation, honoraria

    Editorial Boards:

    1. International Journal of MS Care, editor, 2011- present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Greenwich pharmaceuticals (3) Biogen (4) EMDSerono, (5) Sanofi/Genzyme

    Speakers' Bureaus:

    1. (1) Novartis (2) BristolMyers-Squibb, travel for training

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. EvergreenHealth MS Center, (100%)

    Research Support, Commercial Entities:

    1. (1) Merck (2) Novartis (3) Astellas Stock/Stock Options, Medical Equipment & Materials: (1) Greenwich pharmaceuticals (2020)

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Elisabeth B. Lucassen, MD,
    5. Scientific Advisory Boards:

    1. EMD Serono, Genentech, Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. EMD Serono, Genzyme, Genentech, Novartis, Biogen

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. see above listed companies

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Kyle Smoot, MD,
    6. Scientific Advisory Boards:

    1. Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Allergan, Biogen, EMD Serono, Genzyme, Genentech, Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Allergan, Biogen, EMD Serono, Genzyme, Genentech, Novartis

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen, EMD Serono, Genzyme, Genentech, Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Providence

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Annette Wundes, MD and
    7. Scientific Advisory Boards:

    1. Self: AbbVie, Biogen. Husband: Celgene, Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Self: NA. Husband: Medac, Miltenyi, Novartis,

    Editorial Boards:

    1. NONE

    Patents:

    1. Self: NA. Husband: Medac. New strategy to isolate MSC from bone marrow mononuclear cells

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Idec, Alkermes, AbbVie. Husband: Bayer, Erydel, Miltenyi, Sandoz-Hexal

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society (NMSS), institutional fellowship training grant

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Self: NA. Husband: Royalties (for patent listed above) Medac Stock/Stock Options, Medical Equipment & Materials: Self NA. Husband stocks: Healthineers

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Pavle Repovic, MD, PhD
    8. Scientific Advisory Boards:

    1. (1) Alexion, (2) Biogen, (3) Celgene, (4) Merck, (5) Novartis, (6) Roche, (7) Sanofi, (8) Viela

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Alexion, (2) Biogen, (3) Celgene, (4) Merck, (5) Novartis, (6) Roche, (7) Sanofi, (8) Viela

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Alexion, (2) Biogen, (3) Celgene, (4) Merck, (5) Roche, (6) Sanofi, (7) Viela

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Alexion, (2) Biogen, (3) Roche

    Research Support, Government Entities:

    1. (1) NIH #NS077309 co-principal investigator, 2014-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Swedish Multiple Sclerosis Center (J.D.B., P.R), Seattle, WA; Providence Multiple Sclerosis Center (J.B., E.B.L., K.S.), Portland, Oregon; EvergreenHealth Multiple Sclerosis Center (T.R.B.), Kirkland; and University of Washington Multiple Sclerosis Center (A.W.), Seattle.
  1. Correspondence
    Dr. Repovic pavle.repovic{at}swedish.org
View Full Text

Article usage

Article usage: May 2020 to August 2023

AbstractFullPdfSource
May 2020037495Highwire
Jun 202061469369Highwire
Jul 20200489140Highwire
Aug 2020124889Highwire
Sep 2020354290Highwire
Oct 2020418898Highwire
Nov 2020010544Highwire
Dec 202039528Highwire
Jan 202118742Highwire
Feb 202118631Highwire
Mar 202108224Highwire
Apr 202116427Highwire
May 202108222Highwire
Jun 202117937Highwire
Jul 202106733Highwire
Aug 202125131Highwire
Sep 202105117Highwire
Oct 202105632Highwire
Nov 202104827Highwire
Dec 202104927Highwire
Jan 202203310Highwire
Feb 20221586Highwire
Mar 202203225Highwire
Apr 202203027Highwire
May 202202712Highwire
Jun 202206313Highwire
Jul 20221291Highwire
Aug 202202812Highwire
Sep 202206218Highwire
Oct 202213512Highwire
Nov 202208624Highwire
Dec 20221309Highwire
Jan 202304517Highwire
Feb 202304611Highwire
Mar 202305312Highwire
Apr 202302211Highwire
May 202301812Highwire
Jun 20230106Highwire
Jul 202301514Highwire
Aug 202301411Highwire

Cited By...

Letters: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles